Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- CheckyesterdayChange DetectedRevision history updated: added Revision: v3.3.4 and removed Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter updates: added Revision: v3.3.3 and removed the HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedPublications section updated to state that publications are provided by the entry author and are about the study results; PubMed auto-fill remains, and the revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.2%

- Check58 days agoChange DetectedRemoved the banner notice about a lapse in government funding on the ClinicalTrials.gov page for ARCADIA (NCT03824691), which is an administrative detail rather than core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedNo significant additions or deletions were observed on the ARCADIA study page. The published study details remain unchanged.SummaryDifference0.4%

- Check101 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference2%

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.